FDA
-
-
-
-
-
-
-
Silence Therapeutics (SLN) Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting
-
-
-
-
-
-
-
Virpax Pharmaceuticals Announces Leadership Transition
-
-
-
-
-
-
-
Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia
-
-
-
-
-
-
-
Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

